Details
Category: Volume 09 Issue 09 September 2021
Hits: 727

Title: Polycystic ovary syndrome: Relationship between serum Anti mullerian hormone (AMH) and other reproductive hormones

Authors: Dr Meenakshi Rana, Dr Kamini Randhawa

 DOI: https://dx.doi.org/10.18535/jmscr/v9i9.17

Abstract

Objective: To examine the relationship of serum anti mullerian hormone (AMH), FSH, free-T, LH, and TSH in women with polycystic ovary syndrome (PCOS).

Design: A prospective observational study.

Setting: Departments of Obstetrics and Gynecology IGMC Shimla.

Patient(s): 50 women with PCOS and 50 non PCOS women.

Intervention(s): blood samples were collected on day 2 of menstrual cycle and analysed.

Main Outcome Measure(s): Serum levels of FSH, LH, free-T, TSH, Prolactin, AMH were measured.

Result(s): Serum Anti Mullerian hormone levels were significantly higher in PCOS patients as compared to non PCOS patients.(7.58+_3.93 ng/mL and 2.89+_1.19 ng/ml respectively).

PCOS patients had higher serum LH levels than non pcos patients (10.04+_2.6 mIU/mL).

Conclusion: In this study, PCOS patients have significantly higher serum AMH levels than non PCOS.  And serum LH levels were also higher in PCOS group.

Keywords: Antimullerian hormone (AMH), polycystic ovary syndrome (PCOS).

References

  1. Knochenhauer ES, Key TJ, Kahsar-Miller M, Waggoner W, Boots LR, Azziz R. Prevalence of the polycystic ovary syndrome in unselected black and white women of the Southeastern United States: a prospective J Clin Endocrinol Metab 1998;83:3078–82.
  2. Yen SSC. Polycystic ovary syndrome: hyperandrogenic chronic anovulation.In: Yen SSC, Jaffe RB, Barbieri RL, eds. Reproductive endocrinology, physiology, pathophysiology and clinical management, 4th Philadelphia: WB Saunders, 1999:436–78.
  3. Michelmore KF, Balen AH, Dunger DB, Vessey MP. Polycystic ovaries and associated clinical and biochemical features in young women. Clin Endocrinol 1999;51:779–86.
  4. Orsini LF, Ventruroli S, Lorusso R, Pluchinotta V, Paradisi R, Bovicelli L. Ultrasonic findings in polycystic ovarian disease. 1985;43:709–14.
  5. El Tabbakh GH, Lotfy I, Azab I, Rahman HA, Southren AL, Aleem FA. Correlation of the ultrasonic appearance of the ovaries in polycystic ovarian disease and the clinical, hormonal, and laparoscopic findings. Am J Obstet Gynecol 1986;154:892–5.
  6. Polson DW, Wadsworth J, Adams J, Franks S. Polycystic ovaries—a common finding in normal women. Lancet 1988;1:870–2.
  7. Roberts VJ, Barth S, el-Roeiy A, Yen SS. Expression of inhibin/activin system messenger ribonucleic acids and proteins in ovarian follicles from women with polycystic ovarian syndrome. J Clin Endocrinol Metab 1994;79:1434–9.
  8. Jaatinen TA, Penttila TL, Kaipia A, Ekfors T, Parvinen M, Toppari J. Expression of inhibin alpha, beta A and beta B messenger ribonucleic acids in the normal human ovary and in polycystic ovarian syndrome. J Endocrinol 1994; 143:127–37.
  9. Hernandez ER, Hurwitz A, Payne DW, Dharmarajan AM, Purchio AF, Adashi EY. Transforming growth factor-_1 inhibits ovarian androgen production: gene expression, cellular localization, mechanism(s), and site(s) of action. Endocrinology 1990;127:2804–11.
  10. Chegini N, Flanders KC. Presence of transforming growth factor beta and their selective cellular localization in human ovarian tissue of various reproductive stages. Endocrinology 1992;130:1707–15.
  11. Roby KF, Terranova PF. Effects of tumor necrosis factor-alpha in vitro on steroidogenesis of healthy and atretic follicles of the rat: theca as a target. Endocrinology 1990;126:2711–8.
  12. Andreani CL, Payne DW, Packman JN, Resnick LF, Hurnitz A, Adashi EY. Cytokine-mediated regulation of ovarian function. Tumor necrosis factor-alpha inhibits gonadotropin-supported ovarian androgen biosynthesis. J Biol Chem 1991;266:6761–6.
  13. Takahashi M, Koide S, Donahoe. Mu¨llerian inhibiting substance as oocyte meiosis inhibitor. Mol Cell Endocrinol 1986;47:225–34.
  14. Ueno S, Kuroda T, MacLaughlin DT, Ragin RC, Manganaro TF, Donahoe PK. Mullerian inhibiting substance in the adult rat ovary during various stages of the estrous cycle. Endocrinology 1989;125: 1060–6.
  15. Fallat ME, Siow Y, Marra M, Cook C, Carrillo A. Mu¨llerian inhibiting substance in follicular fluid and serum—a comparison of patients with tubal factor infertility, polycystic ovarian syndrome and endometriosis. Fertil Steril 1997;67:962–5.
  16. Lee MM, Donahoe PK. Mu¨llerian inhibiting substance: a gonadal hormone with multiple functions. Endocr Rev 1993;14:152–64.
  17. di Clemente N, Ghaffari S, Pepinsky R, Pieau C, Josso N, Cate RL, et al. A quantitative and interspecific test for biological activity of anti- Mullerian hormone: the fetal ovary aromatase assay. Development 1992;114:721–7.
  18. Kim JH, Seibel MM, MacLaughlin DT, Donahoe PK, Ransil BJ, Hametz PA, et al. The inhibitory effects of Mu¨llerian-inhibiting substance on epidermal growth factor induced proliferation and progesterone production of human granulosa-luteal cells. J Clin Endocrinol Metab 1992;75:911–7.
  19. Cook CL, Siow Y, Taylor S, Fallat ME. Serum Mu¨llerian inhibiting substance levels during normal menstrual cycle. Fertil Steril 2000;73: 859–61.
  20. Moll GW Jr, Rosenfield RL. Plasma free testosterone in the diagnosis of adolescent polycystic ovary syndrome. J Pediatr 1983;102:461–4.
  21. Emans SJ, Grace E, Woods ER, Mansfield J, Crigler JF Jr. Treatment with dexamethasone of androgen excess in adolescent patients. J Pediatr 1988;112: 821–6.
  22. Muttukrishna S, Fowler PA, Groome NP, Mitchell GG, Robertson WR, Knight PG. Serum concentrations of dimeric inhibin during spontaneous human menstrual cycle and after treatment with exogenous gonadotrophin. Human Reprod 1994; 9:1634–42.
  23. Lockwood GM, Muttukrishna A, Ledger WL. Inhibins and activins in human ovulation, conception and pregnancy. Hum Reprod Update1998;4:284–95.
  24. Gustafson ML, Lee MM, Scully RE, Moncure AC, Hirakawa T, Goodman A, et al. Mu¨llerian inhibiting substance as a marker for ovarian sex-cord tumor. N Engl J Med 1992;326:466–71.
  25. Gustafson ML, Lee MM, Asmundson L, MacLaughlin DT, Donahoe PK. Mu¨ llerian inhibiting substance in the diagnosis and management of intersex and gonadal abnormalities. J Pediatr Surg 1993;28:439 –44.
  26. Lane AH, Lee MM, Fuller AF Jr, Kehas DJ, Donahoe PK, MacLaughlin DT. Diagnostic utility of Mu¨llerian inhibiting substance determination in patients with primary and recurrent granulosa cell tumors. Gynecol Oncol 1999;73:51–5.

Corresponding Author

Dr Meenakshi Rana

Junior Resident, Department of Obstetrics and Gynaecology, IGMC Shimla